Epigenomics' Q1 Revenues Drop 5 Percent

May 10, 2017

|

NEW YORK (GenomeWeb) – Epigenomics today reported a nearly 5 percent decline in first quarter revenues, primarily due to the conclusion of agreements with licensing partners for the sale of its products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Epigenomics' Q1 Revenues Drop 5 Percent

To read the full story....

Breaking News

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Todos Medical Obtains $3.4M Investment From Yozma Group Korea

Infectious Disease Test Firm Talis Biomedical Files for IPO

Roche Renews Agreement to Distribute Sysmex Hematology Products

Rhinostics Licenses Procter & Gamble Nasal Swab for COVID-19 Testing

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Infectious Disease Test Firm Talis Biomedical Files for IPO

NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

President Biden Announces Plan to Expand SARS-CoV-2 Testing, Increase Capacity

Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

NeoGenomics to Grow Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

Sponsorships